Cyclovalone

Cyclovalone

SCHEMBL554418

COc1cc(/C=C2/CCC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
JUN P05412 1/20 1.00
MME P08473 1/20 1.00
NFKB1 P19838 1/20 1.00
NOD2 Q9HC29 1/20 1.00
MAPT P10636 5/20 0.89
MAPK1 P28482 3/20 0.89
KDM4E B2RXH2 3/20 0.89
CYP3A4 P08684 2/20 0.89
POLB P06746 2/20 0.89
CYP1A2 P05177 1/20 0.89
CYP2C9 P11712 1/20 0.89
THRB P10828 1/20 0.89
ATM Q13315 1/20 0.89
GAA P10253 3/20 0.77
LMNA P02545 3/20 0.77
L3MBTL1 Q9Y468 2/20 0.77
JAK2 O60674 1/20 0.77
ALDH1A1 P00352 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclovalone SCHEMBL554417 1.00 MEN1 (1.00) MEN1KMT2AJUNMMENFKB1
Cyclovalone SCHEMBL1151847 1.00 MEN1 (1.00) MEN1KMT2AJUNMMENFKB1
Cyclovalone SCHEMBL29929726 1.00 MEN1 (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL24510580 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL6852865 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL6851610 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL29857079 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL16382595 0.90 MEN1 (0.81) MEN1KMT2AJUNMMENFKB1
SCHEMBL1524530 0.90 MEN1 (0.82) MEN1KMT2AJUNMMENFKB1
SCHEMBL28574116 0.90 MEN1 (0.82) MEN1KMT2AJUNMMENFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
CN-106573084-A Wetness indicator with permanent colorant 宝洁公司 2017-04-19 CN claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8026285-B2 Control release of biologically active compounds from multi-armed oligomers BEZWADA BIOMEDICAL, LLC (US) 2011-09-27 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS BEZWADA BIOMEDICAL, LLC (US) 2009-03-19 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-20260048025-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES NATURAL EXTRACTION SYS LLC (US) 2026-02-19 US disclosed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB MEN1 1711/4885KMT2A 4742/4885JUN 2582/4885
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS MME, CTSA, ALG1 MEN1 1076/4885KMT2A 4319/4885JUN 3578/4885
US-20260048025-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES SCO2, CNR2, CNR1 MEN1 1906/4885KMT2A 4414/4885JUN 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.